Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.

Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM.

Oncologist. 2013;18(9):1022-31. doi: 10.1634/theoncologist.2013-0126. Epub 2013 Jul 23.

2.

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.

Lawrie TA, Rabbie R, Thoma C, Morrison J.

Cochrane Database Syst Rev. 2013 Oct 21;(10):CD010482. doi: 10.1002/14651858.CD010482.pub2. Review.

PMID:
24142521
3.

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J.

Cochrane Database Syst Rev. 2013 Jul 9;(7):CD006910. doi: 10.1002/14651858.CD006910.pub2. Review.

PMID:
23835762
4.

Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials.

Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P.

Cancer Biol Ther. 2014 Jun 1;15(6):707-20. doi: 10.4161/cbt.28557. Epub 2014 Mar 21. Review.

5.

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F.

J Clin Oncol. 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. Epub 2011 Aug 15.

PMID:
21844495
6.
7.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA.

J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.

PMID:
24127448
8.

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A.

J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24.

PMID:
20498395
9.

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.

Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.

PMID:
25722380
10.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

11.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO).

Anticancer Res. 2008 Mar-Apr;28(2B):1329-34.

12.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero A.

Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17.

PMID:
25534295
13.

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; Gynecologic Cancer Intergroup.

Ann Oncol. 2011 Nov;22(11):2417-23. doi: 10.1093/annonc/mdr001. Epub 2011 Mar 14.

PMID:
21402619
14.

Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.

Rakowski JA, Ahmad S, Holloway RW.

Expert Rev Anticancer Ther. 2012 Jan;12(1):31-40. doi: 10.1586/era.11.187. Review.

PMID:
22149430
15.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
16.

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.

Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM.

Eur J Cancer. 2012 Oct;48(15):2361-8. doi: 10.1016/j.ejca.2012.04.001. Epub 2012 Apr 26.

PMID:
22541893
17.

[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].

Zheng H, Gao YN, Jiang GQ, Gao M, Wang W, Yan X.

Zhonghua Fu Chan Ke Za Zhi. 2008 Nov;43(11):839-42. Chinese.

PMID:
19087568
18.

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P.

J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17.

PMID:
22987083
19.

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.

Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, Dimopoulos AM.

BMC Med. 2010 Jan 7;8:3. doi: 10.1186/1741-7015-8-3.

20.

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.

Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17.

PMID:
19446868

Supplemental Content

Support Center